Table 3 Disparities in prescription prevalence pre-diagnosis and post-diagnosis
From: Investigating racial disparities in drug prescriptions for patients with endometriosis
Pre-diagnosis | Post-diagnosis | |||
|---|---|---|---|---|
Drug class | Prevalence difference (SE) (%) | Adjusted p-value | Prevalence difference (SE) (%) | Adjusted p-value |
Anti-infectives and antiseptics, excl. combinations with corticosteroids | −5.09 (1.14) | 0.00012 | −2.81 (1.14) | 0.1921767 |
Anti-inflammatory and antirheumatic products, non-steroids | 1.99 (0.81) | 0.19 | 1.84 (0.93) | 0.67 |
Antidepressants | 25.69 (1.08) | 1.09E−124 | 20.74 (1.12) | 1.69E−75 |
Antiemetics and antinauseants | 7.37 (1.07) | 8.95E−11 | 7.47 (1.05) | 1.32E−11 |
Antiepileptics | 22.92 (1.10) | 1.01E−95 | 17.93 (1.10) | 9.68E−59 |
Antifibrinolytics | −0.31 (0.26) | 3.24 | −0.71 (0.21) | 0.011 |
Antihistamines for systemic use | 7.29 (0.99) | 2.33E−12 | 4.01 (1.12) | 0.0048 |
Anxiolytics | 24.99 (1.11) | 5.24E−112 | 20.71 (1.11) | 2.03E−76 |
Belladonna and derivatives, plain | 4.14 (0.81) | 4.36E−06 | 2.62 (0.67) | 0.0012 |
Corticosteroids for systemic use, plain | 13.90 (1.04) | 1.51E−39 | 9.47 (1.07) | 1.59E−17 |
Cough suppressants, excl. combinations with expectorants | 7.60 (0.82) | 2.71E−19 | 4.72 (0.76) | 6.33E−09 |
Drugs for constipation | −2.86 (1.04) | 0.084 | −2.78 (1.05) | 0.11 |
Drugs for functional gastrointestinal disorders | 6.50 (0.90) | 9.06E−12 | 4.27 (0.85) | 6.23E−06 |
Drugs for peptic ulcer and gastro-esophageal reflux disease (GERD) | 8.31 (1.14) | 4.26E−12 | 8.21 (1.13) | 4.41E−12 |
Estrogens | 3.12 (0.71) | 0.00016 | 9.52 (0.85) | 2.89E−28 |
Hormonal contraceptives for systemic use | −0.37 (1.14) | 10.46 | −1.31 (1.10) | 3.29 |
Hormones and related agents | −8.10 (1.10) | 2.81E−12 | −8.05 (0.97) | 1.29E−15 |
Hypnotics and sedatives | 12.87 (1.13) | 5.88E−29 | 8.23 (1.14) | 7.51E−12 |
Iron preparations | −5.43 (0.74) | 3.29E−12 | −3.41 (0.53) | 1.49E−09 |
Opioids | 3.75 (0.77) | 1.82E−05 | 3.96 (0.81) | 1.26E−05 |
Other analgesics and antipyretics | 10.54 (1.07) | 1.10E−21 | 7.42 (1.11) | 3.13E−10 |
Other diagnostic agents | 1.65 (0.64) | 0.14 | 1.00 (0.57) | 1.10 |
Other systemic drugs for obstructive airway diseases | 1.99 (0.68) | 0.047 | 2.54 (0.66) | 0.0016 |
Progestogens | −5.35 (1.13) | 3.15E−05 | −6.08 (1.02) | 4.08E−08 |
Quinolone antibacterials | 8.50 (0.39) | 1.17E−12 | 6.58 (1.11) | 4.05E−08 |
Selective calcium channel blockers with direct cardiac effects | 0.34 (0.39) | 5.36 | 0.26 (0.33) | 6.06 |
Thyroid preparations | 6.82 (0.57) | 7.63E−32 | 6.42 (0.56) | 5.93E−29 |
Urologicals | 5.64 (0.72) | 5.08E−14 | 6.16 (0.80) | 1.54E−13 |
